A complainant shared four third-party posts on X (formerly Twitter) and two online articles with the PMCPA to make the case ...
US mRNA specialist Moderna demonstrated substantial R&D investment and progress in the UK, two years since signing its ...
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...
Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...
Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...
Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...
Investor's Business Daily on MSN3h
RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box.RFK Jr. cleared a key hurdle Tuesday after the Senate Finance Committee voted along party lines to send his nomination to the full chamber.
Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy.
Zaks was a familiar face in the biotech industry during the Covid pandemic, and due to the meteoric rise in Moderna's share price, he also became very wealthy. Following a signed agreement to sell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback